Ogino M, Sakamoto T, Yamamoto T, Mori H, Okinaga S, Arai K
Department of Obstetrics and Gynecology, Teikyo University School of Medicine, Tokyo, Japan.
Gynecol Oncol. 1990 Jul;38(1):32-6. doi: 10.1016/0090-8258(90)90007-8.
The value of the 6-day subrenal capsule assay (SRCA) in predicting the effectiveness of chemotherapy was tested using three human choriocarcinomas. The SRCA method proved to be a valuable chemopredictive test for choriocarcinoma. The results of experimental chemotherapy in nude mice and the results of the SRCA in two types of choriocarcinoma correlated well. Two of three choriocarcinomas showed sensitivity to MAC combination chemotherapy [methotrexate, actinomycin D, cyclophosphamide), and all three showed greater sensitivity to VP-16. The administration of VP-16 for treatment of all three types of choriocarcinoma significantly reduced tumor size in a dose-dependent fashion. From these observations, we speculate that the SRCA may be applied to assess the effectiveness of chemotherapy against human choriocarcinoma.
使用三种人绒毛膜癌测试了6天肾包膜下测定法（SRCA）在预测化疗有效性方面的价值。SRCA方法被证明是一种用于绒毛膜癌的有价值的化疗预测测试。裸鼠实验化疗结果与两种绒毛膜癌的SRCA结果相关性良好。三种绒毛膜癌中有两种对MAC联合化疗（甲氨蝶呤、放线菌素D、环磷酰胺）敏感，并且三种都对VP-16表现出更高的敏感性。给予VP-16治疗所有三种类型的绒毛膜癌均以剂量依赖性方式显著减小肿瘤大小。基于这些观察结果，我们推测SRCA可用于评估针对人绒毛膜癌的化疗有效性。
